Why Do Red Acne Marks Persist? PIE and Dual Yellow Laser
Persistent pink-red marks after acne may be post-inflammatory erythema (PIE), involving superficial vascular changes. Many improve gradually, while selected persistent cases may be assessed for vascular-focused laser treatment such as Dual Yellow.

How PIE forms
Vascular changes after inflammatory acne can leave pink-red marks for weeks or months.
PIE versus PIH
PIE relates to redness and vessels; PIH involves melanin. Both may coexist.
Why marks persist
Prior inflammation, repeated breakouts and irritation can slow apparent recovery.
When might Dual Yellow help?
Selected persistent vascular marks may be considered for treatment, without a promise of one-session clearance.
Consider colour, duration, ongoing breakouts and whether skin is still inflamed. When acne is controlled but vascular redness persists, a clinician may consider a vascular-targeted option such as 578 nm Dual Yellow. Response and number of sessions cannot be guaranteed.
What if acne is active?
Controlling inflammatory acne first can prevent new marks and reduce irritation.
Tracking results
Use consistent lighting and angles and distinguish old marks from new ones. Worsening symptoms require review.
Frequently asked questions
Does every red acne mark require laser?
No. Some fade gradually, and acne control plus gentle skincare remain essential.
Are red and brown acne marks treated the same way?
Not always. PIE has a vascular component, whereas PIH is related to melanin; treatment targets differ.
Should I have Dual Yellow while acne is still inflamed?
Have the skin examined first. Controlling active acne and irritation is often the priority.
Consult STC Clinic
If you are concerned about persistent redness, visible capillaries or uneven tone, ask an STC Clinic physician to identify the underlying issue and assess whether Dual Yellow or another approach fits your skin.
References
Post-acne erythema treatment: A systematic review (2022) — https://pubmed.ncbi.nlm.nih.gov/35076997/ Post-acne Erythema: Systematic Review of Randomized Trials (2026) — https://pmc.ncbi.nlm.nih.gov/articles/PMC13677114/



Comments